Published in Cancer Weekly, August 16th, 2011
"It is cost-effective to provide surveillance of patients who have a lifetime risk of pancreatic cancer that is >= 16 %. Studies are currently ongoing that contribute to our understanding of the imaging methodologies that are best suited for surveillance and the best algorithm for the clinical management of patients who are at risk of this highly lethal disease," wrote T.A. Brentnall and colleagues, University of Washington.
The researchers concluded:...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.